Success Metrics

Clinical Success Rate
78.4%

Based on 40 completed trials

Completion Rate
78%(40/51)
Active Trials
5(7%)
Results Posted
45%(18 trials)
Terminated
11(16%)

Phase Distribution

Ph not_applicable
6
9%
Ph phase_1
15
21%
Ph early_phase_1
3
4%
Ph phase_3
9
13%
Ph phase_4
3
4%
Ph phase_2
30
43%

Phase Distribution

18

Early Stage

30

Mid Stage

12

Late Stage

Phase Distribution66 total trials
Early Phase 1First-in-human
3(4.5%)
Phase 1Safety & dosage
15(22.7%)
Phase 2Efficacy & side effects
30(45.5%)
Phase 3Large-scale testing
9(13.6%)
Phase 4Post-market surveillance
3(4.5%)
N/ANon-phased studies
6(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

40 of 56 finished

Non-Completion Rate

28.6%

16 ended early

Currently Active

5

trials recruiting

Total Trials

70

all time

Status Distribution
Active(7)
Completed(40)
Terminated(16)
Other(7)

Detailed Status

Completed40
Terminated11
unknown6
Withdrawn5
Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
70
Active
5
Success Rate
78.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (4.5%)
Phase 115 (22.7%)
Phase 230 (45.5%)
Phase 39 (13.6%)
Phase 43 (4.5%)
N/A6 (9.1%)

Trials by Status

not_yet_recruiting23%
suspended11%
terminated1116%
unknown69%
withdrawn57%
recruiting34%
active_not_recruiting23%
completed4057%

Recent Activity

Clinical Trials (70)

Showing 20 of 70 trialsScroll for more
NCT04305457Phase 2

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

Terminated
NCT02836899Phase 3

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

Completed
NCT06622291Phase 4

Perioperative Nitric Oxide Prevents Acute Kidney Injury in Acute Type A Aortic Dissection Patients

Completed
NCT04022161Phase 2

Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients

Withdrawn
NCT03748082Phase 2

Effects of Nitric Oxide on the Endothelium During Hemolysis.

Withdrawn
NCT05109611Phase 3

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Terminated
NCT03023449Phase 2

Diffuse Optical Monitoring With Inhaled Nitric Oxide

Active Not Recruiting
NCT04216927Phase 3

NO During CPB in Neonates to Reduce Risk of AKI

Recruiting
NCT05801224Not Applicable

Vascular ARDS Recruitment After Inhaled Nitric Oxide

Suspended
NCT06675435Not Applicable

Inhaled Nitric Oxide in Severe Obesity

Not Yet Recruiting
NCT06660784

Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance

Active Not Recruiting
NCT01165047Phase 2

Nitric Oxide, GeNO Nitrosyl Delivery System

Completed
NCT04181359Phase 1

The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.

Withdrawn
NCT04231773Phase 1

The Effect of Inhaled Nitric Oxide on Maximal Oxygen Consumption During Exercise in Hypoxia

Completed
NCT06120816Phase 1

Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis

Completed
NCT02295566Phase 2

RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study

Completed
NCT03661385Phase 3

Nitric Oxide During Bypass for Arterial Switch Operation

Completed
NCT05877313Phase 2

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)

Completed
NCT05052229Early Phase 1

Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).

Recruiting
NCT04069052Early Phase 1

The Effect of Inhaled Nitric Oxide on Deadspace in COPD

Completed

Drug Details

Intervention Type
DRUG
Total Trials
70